Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $5.1 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 43.21% year-over-year to $5.1 billion; the TTM figure through Mar 2026 stood at $5.1 billion (up 43.21% YoY), while the FY2025 annual figure was $4.4 billion, up 10.75% from the prior year.
• Total Current Liabilities was $5.1 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $4.4 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.1 billion in Q1 2026 to a low of $2.9 billion in Q3 2022.
• Historically, Total Current Liabilities has averaged $3.6 billion across 5 years, with a median of $3.6 billion in 2025.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities slipped 22.49% in 2022, then soared 43.21% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $3.1 billion in 2022, then grew by 8.98% to $3.4 billion in 2023, then advanced by 15.22% to $3.9 billion in 2024, then increased by 10.75% to $4.4 billion in 2025, then rose by 16.92% to $5.1 billion in 2026.
• The last three Total Current Liabilities figures came in at $5.1 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.4 billion (Q3 2025), per Business Quant data.